Showing 6561-6570 of 19355 results for "".
Food Allergies and Atopic Dermatitis in the Pediatric Population
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/food-allergies-and-atopic-dermatitis-in-the-pediatric-population/37175/Elizabeth Lippner, MD, MA, Attending Physician in the Division of Allergy and Immunology and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, discusses potential links between food allergies and pediatric atopic dermatitis, and how to address them.Applying Real-World Data from SABCS 2025 to HR+ HER2- Breast Cancer Care
https://reachmd.com/programs/project-oncology/real-world-data-sabcs2025-breast-cancer-care/36165/Real-world evidence presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) is helping to identify treatment gaps and guide clinical decision-making for hormone receptor-positive, HER2-negative (HR+ HER2-) advanced breast cancer. From advances in ESR1 testing to explorations of frontline CEnsuring Equity for Your Patients
https://reachmd.com/series/the-practical-dermatology-podcast/ensuring-equity-for-your-patients/54335/Jeanine Downie, MD, FAAD, and an expert panel discuss implicit bias and discrimination against various marginalized populations and how to be proactive in avoiding these problems in your practice. Joining Dr. Downie are Drs. Mona Gohara, Anthony Rossi, Jacob Beer, and Jane Yoo. This discussion is baRedefining ATTR Treatment: Key Mechanisms and Emerging Data
https://reachmd.com/programs/heart-matters/attr-treatment-mechanisms-emerging-data/49057/New therapeutic approaches are reshaping how we think about managing transthyretin amyloidosis (ATTR). Gain insight into the next generation of ATTR therapies as Dr. Ahmad Masri highlights evolving strategies beyond traditional stabilizers. He's an Associate Professor of Medicine in the Division ofAdvances in ATTR-CM: Evolving Diagnostics and Therapeutics
https://reachmd.com/programs/clinicians-roundtable/advances-attr-cm-diagnostics-therapeutics/49055/In the past decade, significant strides have been made in diagnosing and treating patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Increased disease awareness, non-invasive diagnostic tools like scintigraphy, and AI-assisted screening have led to earlier detection and improved outcomes.Continuing the Dry Eye Conversation
https://reachmd.com/podcasts/to-the-point/continuing-the-dry-eye-conversation/54334/Kicking off the first episode of the To the Point podcast in 2026, co-hosts Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, FAAO, continue the dry eye conversation with DED pearls to implement in clinic. They cover everything from patient signs, symptoms, and side effects to in-office tools, treatBeyond Symptom Control: Optimizing Functional Outcomes in Schizophrenia Care
https://reachmd.com/programs/neurofrontiers/beyond-symptom-control-optimizing-functional-outcomes-in-schizophrenia-care/36646/Functional recovery—not just symptom reduction—is becoming the new standard in schizophrenia care. Given this shift, psychiatric nurse practitioner Ashley Baker speaks with Dr. Stephen Marder about how integrated treatment models combining pharmacologic and psychosocial interventions can improve funExpert Opinions on Characteristics of Patients With C3G at High Risk of Progression
https://reachmd.com/programs/medical-industry-feature/c3g-high-risk-progression-characteristics/39255/A variety of indicators can help provide important information on disease progression in patients with complement 3 glomerulopathy (C3G). Hear from Drs Dana Rizk, Carla Nester, Sanjeev Sethi, and Leal C. Herlitz as they share their perspectives. Dr Rizk is a Professor of Medicine in the Division ofThe Hidden Respiratory Burden of Obesity: Understanding the Clinical Consequences
https://reachmd.com/programs/clinicians-roundtable/the-hidden-respiratory-burden-of-obesity-understanding-the-clinical-consequences/39650/Obesity introduces distinct changes to respiratory physiology that ripple across care settings—from subtle outpatient symptoms to complex ventilatory challenges in the ICU and heightened perioperative risks. Dr. Sujith Cherian explains real-world scenarios and physiologic insights to show how excessExploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
https://reachmd.com/programs/Audioabstracts/survival-elderly-patients-attr-cm-tafamidis/49053/A new analysis from the HEAR registry revealed that tafamidis is associated with significantly improved three-year survival in patients aged 80 and older with transthyretin cardiac amyloidosis (ATTR-CM). Hear from Dr. Hallie Blevins as she discusses this large real-world dataset and the importance o